Investigation and Characterization of the RAS/RAF/MEK/ERK Pathway and Other Signaling Pathways in Chronic Sinusitis with Nasal Polyps DOI

Zhipu Niu,

Jichao Sha,

Dongdong Zhu

et al.

International Archives of Allergy and Immunology, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 12

Published: Oct. 1, 2024

Background: The clinical outcomes of drug treatments and surgical interventions for chronic sinusitis with nasal polyps (CRSwNPs) are suboptimal, the high recurrence rate remains a significant challenge in practice. Targeted therapies such as biologics provide new perspectives directions treating CRSwNP. Summary: With continuous investigation signaling pathways, RAS/RAF/MEK/ERK pathway other pathways including Hippo, JAK-STAT, Wnt, TGF-β, PI3K, Notch, NF-κB were confirmed to play an important role progression Among them, abnormality is accompanied by this apoptotic component, which may research targeting components mediate apoptosis. Key Messages: Abnormalities particularly studying pathogenesis treatment Therefore, review summarizes ongoing characterization CRSwNP, provides constructive ideas improving

Language: Английский

Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient DOI Creative Commons
Linda Rogers, Miloš Jeseňák, Leif Bjermer

et al.

Respiratory Medicine, Journal Year: 2023, Volume and Issue: 218, P. 107414 - 107414

Published: Sept. 29, 2023

The development of monoclonal antibody therapies targeting specific components the pathways relevant to asthma pathophysiology has revolutionized treatment severe both in adults and children helped further unravel heterogeneity this disease. However, availability multiple agents, often with overlapping eligibility criteria, creates a need for pragmatic guidance specialists undertaking care patients asthma. In review, we provide an overview data supporting clinical efficacy biologics distinct phenotypes/endotypes. We also focus on role biomarkers treatable traits, including comorbidities, choice biologics, highlight which treatments have been demonstrated be steroid sparing corticosteroid dependent asthma, practical that can drive shared decision making patients. addition, summarize what is known date regarding long-term safety these drugs, lastly, discuss future directions research.

Language: Английский

Citations

25
Exhaled Nitric Oxide as Biomarker of Type 2 Diseases DOI Creative Commons
Mauro Maniscalco, Salvatore Fuschillo, Ilaria Mormile

et al.

Cells, Journal Year: 2023, Volume and Issue: 12(21), P. 2518 - 2518

Published: Oct. 25, 2023

Nitric oxide (NO) is a short-lived gas molecule which has been studied for its role as signaling in the vasculature and later, broader view, cellular messenger many other biological processes such immunity inflammation, cell survival, apoptosis, aging. Fractional exhaled nitric (FeNO) convenient, easy-to-obtain, non-invasive method assessing active, mainly Th2-driven, airway sensitive to treatment with standard anti-inflammatory therapy. Consequently, FeNO serves valued tool aid diagnosis monitoring of several asthma phenotypes. More recently, evaluated respiratory and/or immunological conditions, including allergic rhinitis, chronic rhinosinusitis with/without nasal polyps, atopic dermatitis, eosinophilic esophagitis, food allergy. In this review, we aim provide an extensive overview current state knowledge about biomarker type 2 outlining past recent data on application measurement patients affected by broad variety atopic/allergic disorders.

Language: Английский

Citations

24
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care DOI Creative Commons
Peter W. Hellings, Isam Alobid,

Wilma Terezinha Anselmo‐Lima

et al.

Allergy, Journal Year: 2023, Volume and Issue: 79(5), P. 1123 - 1133

Published: Dec. 18, 2023

Abstract Following the European Forum for Research and Education in Allergy Airway Diseases (EUFOREA) treatment algorithm chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin after desensitization (ATAD). Given major differences indications, outcomes, practical considerations, risks costs of these key pillars treatment, there is a growing need define criteria each option list clinically relevant considerations them. This EUFOREA document therefore provides an expert panel overview expected specific (contra)indications five arms CRSwNP: primary revision biological ATAD. needed allow physicians consider different options context providing optimal personalized care CRSwNP. In conclusion, have intrinsic advantages, indications that importance patient, physician society. statement supports unmet indication every pillar

Language: Английский

Citations

21
Eosinophils—from cradle to grave DOI
Miloš Jeseňák, Zuzana Diamant, Dagmar Simon

et al.

Allergy, Journal Year: 2023, Volume and Issue: 78(12), P. 3077 - 3102

Published: Sept. 13, 2023

Abstract Over the past years, eosinophils have become a focus of scientific interest, especially in context their recently uncovered functions (e.g. antiviral, anti‐inflammatory, regulatory). These versatile cells display both beneficial and detrimental activities under various physiological pathological conditions. Eosinophils are involved pathogenesis many diseases which can be classified into primary (clonal) secondary (reactive) disorders idiopathic (hyper)eosinophilic syndromes. Depending on biological specimen, eosinophil count different body compartments may serve as biomarker reflecting underlying pathophysiology and/or activity distinct therapy‐driving (predictive) monitoring tool. Personalized selection an appropriate therapeutic strategy directly or indirectly targeting increased number should based understanding homeostasis including interactions with other immune non‐immune within compartments. Hence, restoring well maintaining individual's pool is goal specific non‐specific eosinophil‐targeting therapies. Despite overall favourable safety profile currently available anti‐eosinophil biologics, effect depletion monitored from perspective possible unwanted consequences.

Language: Английский

Citations

18
Brazilian guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps ‒ 2024 update DOI Creative Commons

Wilma Terezinha Anselmo‐Lima,

Fabrizio Ricci Romano, Edwin Tamashiro

et al.

Brazilian Journal of Otorhinolaryngology, Journal Year: 2024, Volume and Issue: 90(3), P. 101394 - 101394

Published: Jan. 30, 2024

Biologics targeting type 2 inflammation have revolutionized the way we treat patients with Chronic Rhinosinusitis Nasal Polyps (CRSwNP). Particularly in severe and difficult-to-control cases, these drugs provided a new reality for patients, allowing effective safe treatment of extensive diseases that were not completely managed typical strategy surgery topical medications. The experience achieved approval medications by ANVISA use CRSwNP knowledge obtained regarding outcomes, adverse effects, ideal patient profile prompted update previously published guideline, detailed review most recent scientific literature, personal experiences experts, adaptation to Brazilian healthcare system, both public private. We proposed eligibility criterion biologics based on four pillars indication: impact disease patient's life, whether presence specific symptoms or overall quality life; extent sinonasal disease; comorbidities, considering other associated may also benefit from anti-T2 biologics, biomarkers define inflammation, especially those worse prognoses. This innovative pioneering method has two major advantages. First, it ensures comprehensive evaluation patients; second, is flexible, as advancements our understanding changes cost-effectiveness can be addressed simply adjusting required score indication, without need modify entire scheme.

Language: Английский

Citations

4
Tezepelumab improved chronic rhinosinusitis with nasal polyps in a Patient with aspirin exacerbated respiratory disease DOI Creative Commons

Yuga Yamashita,

Kosuke Terada,

Yuka Kodama

et al.

Respiratory Medicine Case Reports, Journal Year: 2024, Volume and Issue: 50, P. 102041 - 102041

Published: Jan. 1, 2024

Patients with chronic rhinosinusitis nasal polyps (CRSwNP) and aspirin-exacerbated respiratory disease (AERD) have more severe sinus than those without AERD. CRSwNP associated type 2 inflammation AERD can be difficult to control standard medical therapy surgery.

Language: Английский

Citations

4
Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR) DOI
Sven Seys, Sven Schneider,

Joost de Kinderen

et al.

Journal of Allergy and Clinical Immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

4
Unveiling and validating biomarkers related to the IL-10 family in chronic sinusitis with nasal polyps: insights from transcriptomics and single-cell RNA sequencing analysis DOI Creative Commons

Xing-pu Liu,

Peng Yi,

Ling Guo

et al.

Frontiers in Molecular Biosciences, Journal Year: 2025, Volume and Issue: 11

Published: Jan. 3, 2025

Extensive efforts have been made to explore members of the IL-10 family as potential therapeutic strategies for various diseases; however, their biological role in chronic rhinosinusitis with nasal polyps (CRSwNP) remains underexplored. Gene expression datasets GSE136825, GSE179265, and GSE196169 were retrieved from Expression Omnibus (GEO) analysis. Candidate genes identified by intersecting differentially expressed (DEGs) between CRSwNP control groups (DEGsall) those high- low-score within cohort (DEGsNP). Biomarker selection was performed using Least Absolute Shrinkage Selection Operator (LASSO), Support Vector Machine Recursive Feature Elimination (SVM-RFE), Boruta algorithm. Further refinement biomarkers carried out receiver operating characteristic (ROC) analysis, demonstrating an area under curve (AUC) greater than 0.7 being considered significant. Genes exhibiting consistent trends significant differences across both GSE136825 GSE179265 selected biomarkers. Cell-type annotation on GSE196169, profiles cell types analyzed. A competing endogenous RNA (ceRNA) network a biomarker-drug interaction also established. Additionally, mRNALocater database utilized determine cellular localization The intersection 1817 DEGsall 24 DEGsNP yielded 15 candidate genes. filtering through LASSO, SVM-RFE, led identification seven biomarkers: PRB3, KRT16, MUC6, SPAG4, FGFBP1, NR4A1, GSTA2. Six these demonstrated strong diagnostic performance while four biomarkers, showing trends, validated GSE136825. Single-cell sequencing analysis revealed distinct types, including endothelial cells, predominantly epithelial cells. ceRNA comprised nine nodes eleven edges, only FGFBP1 complete lncRNA-miRNA-mRNA interaction. This study identifies several novel associated drugs therapy, well targets, such spiperone arnenous acid, molecular docking. Ultimately, this work underscores family-related providing theoretical foundation future clinical research CRSwNP.

Language: Английский

Citations

0
Immunology of Nasal Polyposis and Allergic Rhinitis DOI
Sven Schneider, Julia Eckl‐Dorna

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

0
Chronic Rhinosinusitis, Asthma, and Gastroesophageal Reflux: Epidemiology, Pathophysiology, and Comorbidity DOI Creative Commons

Y S Sun,

Li-Yuan Zhang

Allergy medicine., Journal Year: 2025, Volume and Issue: unknown, P. 100036 - 100036

Published: Feb. 1, 2025

Language: Английский

Citations

0